A three part webinar on the use of medications to treat addiction, including opioid use disorder, for adolescents and young adults hosted by the top OASAS medical...
Frequently asked questions and recommendations to support Opioid Treatment Programs (OTPs) operating in the wake of the evolving COVID-19 situation in New York State.
Patients may now be initiated on buprenorphine through the use of telepractice in accordance with DEA guidance that is in effect during the state of emergency.
OASAS guidance on the administration and dispensing of narcotic medications to treat opioid use disorders including information on the Data 2000 waiver.
Guidance for OASAS-certified Part 822 Opioid Treatment Programs (OTPs) on nursing practices and Medication-assisted Treatment (MAT) for incarcerated individuals. Issued 9/2019
FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks.
New York State Department of Health and Office of Alcoholism and Substance Abuse Services best practices for implementing transmucosal buprenorphine for the treatment of opioid use...
